HC Wainwright & Co. Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $40
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $40.
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $40.